Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study

NCT06843681 · clinicaltrials.gov ↗

PHASE2

Phase

ENROLLING_BY_INVITATION

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Breast Carcinoma in Situ

Interventions

DRUG: Trastuzumab combined with taxane neoadjuvant therapy

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Collaborators

[object Object]